

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau**335**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | | |
|--|---|--|--|--|
| (51) International Patent Classification ⁶ : A61K 35/78 | A1 | (11) International Publication Number: WO 98/17292 (43) International Publication Date: 30 April 1998 (30.04.98) | | |
| (21) International Application Number: PCT/DK97/00457 | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). | | |
| (22) International Filing Date: 20 October 1997 (20.10.97) | | | | |
| (30) Priority Data: 1158/96 21 October 1996 (21.10.96) DK 60/031,395 19 November 1996 (19.11.96) US | | | | |
| (71)(72) Applicant and Inventor: SLOTH-WEIDNER, Morten [DK/DK]; Solbakken 7, DK-2830 Virum (DK). | Published <i>With international search report.</i> | | | |
| (74) Agent: HOFMAN-BANG & BOUTARD, LEHMAN & REE A/S; Hans Bekkevolds Allé 7, DK-2900 Hellerup (DK). | | | | |
| (54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING PARTHENIUM INTEGRIFOLIUM OR PARTS THEREOF OR AN EXTRACT OR COMPONENT THEREOF, THE USE OF SUCH PLANT MATERIAL FOR PREPARING CERTAIN MEDICINES, AND A METHOD OF PREPARING AN EXTRACT OF PARTHENIUM INTEGRIFOLIUM | | | | |
| (57) Abstract | | | | |
| The plant Parthenium integrifolium or parts thereof or an extract or component thereof can be used for preparing medicines for the enhancement of the TH2 pathway of the immune system, the enhancement of the levels of interleukin-4 and interleukin-10, the selective suppression of cyclooxygenase-2 (COX-2), and more specifically for the alleviation of pain, in particular migraine or headache, and for the treatment or prevention of inflammatory or autoimmune disorders. Extracts of the plant can i.a. be obtained by extraction or by steam or vacuum distillation of fresh or dried Parthenium integrifolium or parts thereof, preferably the root. Extraction may be performed with a number of different organic solvents, preferably water miscible solvents, and mixtures thereof with water. After the primary extraction process a second step of processing, such as liquid-liquid extraction, column chromatography, steam distillation or vacuum distillation, can be employed to remove or to concentrate and possibly isolate any constituent of the extract. | | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

Pharmaceutical compositions containing *Parthenium integrifolium* or parts thereof or an extract or component thereof, the use of such plant material for preparing certain medicines, and a method of preparing an extract
5 of *Parthenium integrifolium*

FIELD OF THE INVENTION

The present invention relates to the plant *Parthenium integrifolium* and more specifically to pharmaceutical compositions derived from it as well as the use of *Parthenium integrifolium* or parts thereof or an extract or component thereof for the preparation of medicines for the alleviation of pain or for the treatment or prevention of inflammatory or autoimmune disorders. The invention also relates to a method of preparing an extract of *Parthenium integrifolium* and to the extracts prepared by the method.

BACKGROUND OF THE INVENTION

20 *Parthenium integrifolium* (L.) (family Asteraceae), also commonly known as Missouri snake root, grows wild in woodland and prairies of North America. The herb is 30-130 cm high with numerous white flowerheads forming a flat inflorescence up to 25 cm wide. The root is comprised of a short, conical or bulbshaped headstem that has a diameter of up to 4 cm and elongated secondary, twisted branches leading from the headstem.

30 A number of chemicals have been identified as major components of *Parthenium integrifolium* extracts. One group are the sesquiterpene lactones represented by tetraneurin E and tetraneurin C. Another group are the sesquiterpene esters represented by echinadiol cinnamate, epoxy echinadiol cinnamate, echinaxanthol cinnamate and dihy-

droxynardol cinnamate. Yet another group are the flavonoids represented by quercetagetin methyl ethers and their O-glycosides. Another characteristic component of *Parthenium integrifolium* is pyromeconic acid. Other 5 chemicals present in the plant are coumarins and diverse phenolic glycosides.

The German patent application, publication no. 36 38 715 A1 describes the above mentioned sesquiterpene esters derived from *Parthenium integrifolium*. According to the experimental section of that application, immunological activity tests of the sesquiterpene esters showed that they enhanced granulocyte phagocytosis in vitro up to 30%. This effect is to be considered a pro-inflammatory action 15 related to the non-specific part of the immune system (the reticuloendothelial phagocytic system).

At present the nonsteroidal antiinflammatory drugs (NSAIDs) are the most commonly applied therapeutic agents 20 for the treatment of conditions associated with inflammation and pain. The NSAIDs exert their action by inhibiting the prostaglandin-generating enzyme cyclooxygenase (COX). There are two biochemical subtypes of cyclooxygenase denominated COX-1 and COX-2. COX-1 is constitutively 25 expressed in most cells and is responsible for the formation of prostaglandins which mediate important basic physiological functions, e.g. providing an intact mucosa in the ventricle. COX-2 is not normally present, but may be induced by certain serum factors, cytokines and growth 30 factors and responsible for the formation of inflammatory prostaglandins which mediate many symptoms of inflammation. The NSAIDs are generally non-selective, meaning that they inhibit both COX-2 and COX-1 resulting in an antiinflammatory and pain relieving effect due to the inhibition of COX-2 and a number of side effects due to the 35

inhibition of COX-1, of which gastric ulceration is one of the most important.

Autoimmune disorders like multiple sclerosis, morbus Crohn, rheumatoid arthritis, diabetes mellitus, etc. are associated with an overactivation of the inflammatory arm of the immune system (Th_1 pathway) leading to well known symptoms and serious tissue destruction. The most well established treatment for these disorders is the management of corticosteroids which exert their action by non-selectively inhibiting the function and proliferation of different types of immune cells. Unfortunately the corticosteroids are associated with a number of serious side effects e.g. immuno-suppression and osteoporosis.

15

SUMMARY OF THE INVENTION

I have found that *Parthenium integrifolium* or parts thereof or an extract or component thereof exert the following pharmacological actions: Enhancement of the Th_2 pathway of the immune system, enhancement of the levels of interleukin-4 and interleukin-10, suppression of cyclooxygenase-2 (COX-2), reduction of chronic and acute pain, and reduction of inflammation. Compared to the NSAIDs *Parthenium integrifolium* or parts thereof or an extract or component thereof have the advantage that they are not associated with gastrointestinal and renal side effects. Further, by enhancing the formation of interleukin-4 and interleukin-10 they have a down regulating effect on the Th_1 pathway of the immune system without exerting the serious side effects characteristic of the corticosteroids. Due to these effects *Parthenium integrifolium* or parts thereof or an extract or component thereof can be employed for the following therapeutic applications:

- Alleviation of pain.
- Treatment or prevention of inflammatory or autoimmune disorders.

5

Accordingly the present invention provides a pharmaceutical composition containing *Parthenium integrifolium* or parts thereof or an extract or component thereof and a pharmaceutically acceptable carrier.

10

More specifically the present invention provides the use of *Parthenium integrifolium* or parts thereof or an extract or component thereof for preparing a medicine for the enhancement of the TH2 pathway of the immune system, 15 for the enhancement of the levels of interleukin-4 and interleukin-10, and for the selective suppression of COX-2.

Thus, according to the invention *Parthenium integrifolium* 20 or parts thereof or an extract or component thereof can be used in a method for the alleviation of pain in an individual, which comprises administering such plant material or a pharmaceutical composition containing it to said individual; and the invention comprises the use of 25 *Parthenium integrifolium* or parts thereof or an extract or component thereof for preparing a medicine for the alleviation of pain.

Also, according to the invention *Parthenium integrifolium* 30 or parts thereof or an extract or component thereof can be used in a method for the treatment or prevention of an inflammatory or autoimmune disorder in an individual, which comprises administering such plant material or a pharmaceutical composition containing it to said individual; and the invention comprises the use of *Parthenium integrifolium* or parts thereof or an extract or component 35

thereof for preparing a medicine for the treatment or prevention of inflammatory or autoimmune disorders.

Further, the invention provides a method of preparing an
5 extract of *Parthenium integrifolium*, which comprises ex-
tracting said plant or parts thereof, preferably the
root, with an extraction agent comprising an organic sol-
vent or a mixture thereof with water and subsequently, if
necessary, removing the extraction agent to obtain an ex-
10 tract suitable for utilisation.

DETAILED DESCRIPTION OF THE INVENTION

Surprisingly it has been found that *Parthenium integrifo-*
15 *lum* or parts thereof or an extract or component thereof
exert pharmacological actions relevant to the therapeutic
treatment of conditions associated with pain, inflamma-
tion and autoimmunity.

20 More specifically *Parthenium integrifolium* or parts
thereof or an extract or component thereof provide the
following pharmacological effects upon administration to
the living organism:

- 25 • Enhancement of the TH2 pathway of the immune system.
- Enhancement of the levels of interleukin-4 and inter-
leukin-10.
- 30 • Suppression of COX-2 without affecting COX-1.
- Reduction of pain.
- Reduction of inflammation.

These actions provide part of the rationale for the following therapeutic applications of Parthenium integrifolium or parts thereof or extracts or components thereof:

5 • A method for the treatment of any condition associated
 with pain or inflammation characterised by the admini-
 stration of Parthenium integrifolium or parts thereof
 or an extract or component thereof. The applicant puts
10 forward the hypothesis that the antiinflammatory and
 pain relieving action is due to enhanced levels of in-
 terleukin-4 and -10 which on one hand down regulate the
 inflammatory part of the immune system (TH1 pathway)
15 and on the other hand reduce the expression of COX-2
 leading to a lower level of inflammatory prostagland-
 ins. This mechanism of action holds the advantage com-
 pared to conventional nonsteroidal antiinflammatory
 drugs (NSAIDs) that COX-1 is not inhibited whereby gas-
 tric ulceration and renal side effects are avoided. In
20 a preliminary clinical observation a patient with pain
 and inflammation due to osteoarthritis in the lower
 back experienced a significant improvement after treat-
 ment with 250 mg a day of the extract of Parthenium in-
 tegrifolium described in example 1. The patient was
25 subjected to an oral dose of 125 mg of the extract
 twice a day, administered in a hard gelatine capsule.
 The improvement which consisted in a total elimination
 of pain and increased mobility in the affected joints
 was apparent on day 2 of treatment and continued for
 the entire period of treatment during 3 weeks. After
30 termination of the treatment the pain returned after
 two days. The clinical improvement is attributed to the
 above mentioned effects of Parthenium integrifolium. In
 the clinical pilot study described in example 4 pa-
 tients (n=16) suffering from migraine headache were
35 subjected to a daily dose of an extract of Parthenium
 integrifolium. The study schedule consisted of four pe-

riods of four weeks. The first period served as a base-line, where no treatment was employed. In the second period a daily dose of 200 mg Parthenium integrifolium extract was employed. In the third period a daily dose of 100 mg Parthenium integrifolium extract was employed. In the fourth period a daily dose of 200 mg Parthenium integrifolium extract was employed. During the four periods all incidences of migraine headache were recorded. The incidence of migraine headache was reduced in all of the treatment periods as compared to the baseline period. In the last treatment period the incidence of migraine headache was reduced by 57%, which was statistically significant ($p<0,05$; Wilcoxon). The observed clinical improvement is attributed to the above mentioned effects of Parthenium integrifolium.

- A method for the treatment of inflammatory and autoimmune disorders characterised by the administration of Parthenium integrifolium or parts thereof or an extract or component thereof. The applicant puts forward the hypothesis that the therapeutic action is due to enhanced levels of interleukin-4 and -10 which down regulate the T_H1 pathway of the immune system which plays a significant role in the pathogenesis of inflammatory and autoimmune disorders. Furthermore interleukin-4 and -10 down regulate the expression of COX-2 leading to a decreased formation of inflammatory prostaglandins and a reduction of symptoms of acute inflammation. The therapeutic action may be relevant to all known autoimmune or inflammatory diseases and the following examples are not limiting with respect to this: Autoimmune hepatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hemolytic anemias, Grave's disease, Myastenia gravis, Type 1 Diabetes Mellitus, Inflammatory myopathies, Multiple sclerosis, Hashimoto's thyroiditis, Autoimmune adrenalitis, Crohn Dis-

ease, Ulcerative Colitis, Glomerulonephritis, Progressive Systemic Sclerosis (Scleroderma), Sjögren's Disease, Lupus Erythematosus, Primary vasculitis, Reumatoid Arthritis, Juvenile Arthritis, Mixed Connective 5 Tissue Disease, Atopic Dermatitis, Psoriasis, Pemfigus, Pemfigoid, Dermatitis Herpetiformis, etc.

The preferred embodiment of the invention is an extract of Parthenium integrifolium. Extracts according to the 10 invention can i.a. be obtained by extraction or by steam or vacuum distillation of fresh or dried Parthenium integrifolium or parts thereof, preferably the root. Extraction may be performed with a number of different organic solvents, preferably water miscible solvents, and 15 mixtures thereof with water. The extraction can be performed hot or cold by the employment of any extraction technology e.g. maceration, percolation or supercritical extraction.

20 The preferred extraction solvents are acetone, methyl ethyl ketone, ethyl acetate, lower alkanols having 1 to 4 carbon atoms and mixtures thereof with water. The preferred extraction temperature is close to the boiling point of the employed solvent due to extraction efficacy, 25 but lower temperatures are also applicable making necessary a longer period of extraction.

By changing the composition of the applied solvent the 30 extraction can be made more selective for certain constituents of Parthenium integrifolium thus enhancing or reducing their content in the finished extract. For example the content of phenolic glycosides can be increased by employing a more hydrophilic solvent while the content of sesquiterpenes in the finished product can be enhanced 35 by employing a more lipophilic solvent.

After the primary extraction process a second step of processing, such as liquid-liquid extraction, column chromatography, steam distillation or vacuum distillation, can be employed to remove or to concentrate and 5 possibly isolate any constituent of the extract. Hereby any constituent of *Parthenium integrifolium* can be avoided or concentrated in the finished extract, e.g. pyromeconic acid, sesquiterpene lactones like tetraneurin E and tetraneurin C, sesquiterpene esters like echinadiol 10 cinnamate, epoxy echinadiol cinnamate, echinaxanthol cinnamate and dihydroxnardol cinnamate, flavonoids like quercetagetin methyl ethers and their O-glycosides, coumarins or various phenolic glycosides. Thus the content 15 of any component of *Parthenium integrifolium* can be standardised in the finished extract for the purpose of manufacturing a pharmaceutical composition.

According to the invention *Parthenium integrifolium* or parts thereof or an extract or component thereof can be 20 combined with any other active ingredient or plant extract to potentiate the therapeutic action. Consequently, we propose to combine *Parthenium integrifolium* or parts thereof or extracts or components thereof with eicosapentaenoic acid from fish oils or γ -linolenic acid for the 25 treatment of inflammatory or autoimmune disorders. As a parallel, we propose to combine *Parthenium integrifolium* or parts thereof or extracts or components thereof with *Zingiber officinale* or parts thereof or extracts or components thereof for the treatment of pain and inflammation. 30

Furthermore it is obvious that in the use according to the invention for preparing medicines *Parthenium integrifolium* or parts thereof or an extract or component thereof may be mixed with additives such as surfactants, 35 solvents, thickeners, stabilisers, preservatives, anti-

oxidants, flavour etc. to obtain a desirable product formulation. Similarly, the pharmaceutical compositions according to the invention may further contain such additives. There are no limitations to the dosage form of the 5 formulation, but tablets, gelatine capsules, fluids or granulates are envisaged. Optionally, the composition may also contain surfactants such as bile salts or polyoxyethylene-sorbitan-fatty acid esters for improving dispersibility of the composition in the digestive fluids 10 leading to improved bioavailability or for obtaining the final dosage form of the composition.

EXAMPLES

15 **Example 1**

An extract of *Parthenium integrifolium* according to the invention was prepared as follows:

20 100 g dried root of *Parthenium integrifolium* was extracted with 1500 ml of boiling 90 % ethanol for 4 hours. Thereafter the extract was filtered and evaporated to dryness under vacuum. Thus 22 g of an amber-coloured crystalline extract was obtained suitable for the manufacture 25 of tablets or hard gelatine capsules.

Example 2

An extract of *Parthenium integrifolium* according to the 30 invention was prepared as follows:

100 g dried root of *Parthenium integrifolium* was extracted with 1500 ml of boiling 96 % ethanol for 5 hours. Thereafter the extract was filtered and evaporated to dryness under vacuum. 15 g of an amber-coloured crystal- 35

line extract was obtained. This *Parthenium integrifolium* extract was diluted in 30 ml 80 % ethanol, and to this was added 15 g of acetylated monoglyceride and 5 g of polyoxyethylene-sorbitan-monooleate (Tween 80). Thus a 5 liquid extract was obtained suitable for the manufacture of soft gelatine capsules.

Example 3

10 Materials and Methods

Mice

BALB/c mice, 5-6 weeks old were purchased from Gl. Bom-
15 holtgaard, Ry, Denmark. Unless otherwise specified they were fed standard food pellets and water ad libitum.

Test compound (extract of Parthenium integrifolium)

20 An extract of *Parthenium integrifolium* according to the invention was prepared as follows:

100 g dried root of *Parthenium integrifolium* was ex-
tracted with 1500 ml of boiling 80 % ethanol for 3 hours.
25 Thereafter the extract was filtered and evaporated to dryness under vacuum. Thus 24 g of an amber-coloured crystalline extract was obtained. This *Parthenium integrifolium* extract is abbreviated PI in the rest of this example.

30

Feeding regime

Mice were fed crushed ordinary mouse pellets and water ad libitum. Crushed mouse pellets were exposed to PI or pla-
35 cebo: An ethanolic solution of PI was prepared and mixed

with crushed standard mouse pellet. After drying the content of PI was 6 mg/kg mouse pellet. A mouse was estimated to consume 5 g standard mouse pellet a day resulting in a daily intake of 0,30 mg PI corresponding to a 5 daily dosage of 10 mg/kg at an average body weight of 30 g/mouse. The control diet was prepared by substituting the PI ethanolic solution with pure ethanol in the above mentioned procedure.

10 *Reagents*

Sheep red blood cells (SRBC) were purchased from Statens Serum Institut, Copenhagen Denmark. Antibodies for Elisa assay were purchased from Pharmingen, San Diego, California, U.S.A (see below). The SRBC were washed three times 15 in physiological saline prior to use.

SRBC plaque forming cells (SRBC-PFC)

20 Four days after intravenous injection of 0.2 ml 10% SRBC in physiological saline, the mice were sacrificed and their spleens removed and homogenised by pressing the organs gently through a metal net. The cells were counted and mixed with SCRIB and rabbit complement, and the cell 25 mixture transferred to a reaction chamber (Cunningham and Stzenberg) for quantitation of SRBC-PFC. Four individual assay chambers were counted per splenocyte preparation. The numbers of PFC were calculated as numbers per 10^6 splenocytes.

30

Anti-SRBC antibody titres

Mice were injected intraperitoneally with 10% SRBC in 35 physiological saline in a volume of 0.5 ml. One hundred ml blood were collected from the retroorbital venous plexus at day 3, 6 and 9 post immunisation and trans-

ferred to vials containing 100 ml saline with 2 units of heparin. Plasma (50% dilution) was recovered by centrifugation and serial dilutions performed in round bottom microtitre plates (Nunc, Roskilde, Denmark). SRBC 0.1% and 5 freshly diluted rabbit complement (Glapco, Jylland, Denmark) was added and the plates were incubated at 37°C for 2 hours. Hemolysin titers of individual plasma samples were read by eye as the highest plasma dilution giving total lysis of the added SRBC.

10

Mixed Lymphocyte Culture (MLC)

Spleen cells obtained from pools of 5 spleens were cultured in volumes of 10 ml (2×10^6) per ml in 25 ml T 15 flasks and stimulated with irradiated C57BL6 splenocytes (10^6 /ml). One ml culture supernatants were removed at day 3 and 4 of culture for cytokine determination.

20

Cytokines secreted by MLC responder cells

Elisa assays for IL-2, IL-4 and IL-10 were set up using reagents from Pharmingen: IL-2 standard 1921IU, IL-4 standard 1923IW and IL-10 standard 1228IV. Antibodies: anti-IL-2 18161D, anti-IL4 18031D and anti-IL-10 1814ID 25 (capture Abs), anti-IL-2 18172D, anti-IL-4 18042D and anti-IL-10 18152D (biotinylated detection Abs). Dose-response cytokine standard curves were generated. The three different cytokines secreted by the MLC responder cells at day 3 and 4 of culture were determined from replicate dilutions of the MLC culture supernatants. The linear part of the standard cytokine curves were used to determine the amounts of the individual cytokines.

Statistics

Wilcoxon rank sum test for paired differences and Fischers exact test were used for comparing anti-SRBC antibody titers and SRBC-PFC numbers respectively in PI and placebo fed mice.

Results

Both PI and placebo fed animals tolerated crushed mouse pellets well and no weight loss was registered in any of the experimental or placebo treated mice.

SRBC-PFC

The individual numbers of SRBC-PFC per 10^6 splenocytes of two groups of 21 mice were derived from three separate experiments. The mice were fed PI or placebo for ten consecutive days and immunised with SRBC at day 6 and killed at day 10 of the feeding regime. The mean numbers of SRBC-PFC per 10^6 splenocytes in the two groups were 400 and 220, respectively. However, these numbers were not statistically different ($p>0.05$, Wilcoxon). However, some differences among the two groups of mice were encountered. Thus, six of the 21 mice in the PI fed group and only 1 of 21 mice in the placebo group produced more than 500 PFC per 10^6 splenocytes, this difference between the two groups being significant ($p<0.02$, Fisher's exact test). Moreover, when the ten mice producing the highest number of SRBC-PFC in each of the two groups were compared the difference between these two high responding "subgroups" was significant ($P<0.05$, Wilcoxon).

Anti-SRBC hemolysins

The results from the SRBC-PFC study prompted us to examine the level of anti-SRBC antibody titers from individual mice fed for 14 days with PI or placebo respectively. Table 1 shows the results. The PI fed group of mice showed significantly higher ($p<0.005$) anti-SRBC titer values at day 6 after immunisation as compared with the placebo fed group of mice.

10

Table 1.

Anti-SRBC hemolysin titres in mice fed EPC-10 or placebo for 12 days. Mice were immunized at day 3 and antibody titers determined 3, 6 and 9 days after immunization.

15

| Days post immunization | <u>MICE FED WITH:</u> | |
|---------------------------|-----------------------|----------------|
| | <u>PI</u> | <u>Placebo</u> |
| 3 | 7 (0-18)* | 18 (0-36) |
| 6 | 691# (576-1152) | 245 (72-288) |
| 20 9 | 202 (144-288) | 115 (72-144) |

* Numbers in parentheses represent the range of titers in five individual mice

Significantly different from the placebo fed group,

25 $p<0.005$ (Wilcoxon)*Cytokines*

Supernatants from the MLC cultures described above were assayed for cytokine content at day 3 and 4 of culture. The amounts of IL-2, IL-4 and IL-10, respectively, were measured in the MLC supernatants by a sensitive ELISA technique. As shown in Table 2, at day 3 of culture, the MLC supernatants from PI fed mice contained two times more IL-2 and IL-10 and seven times more IL-4. At day 4 of culture supernatants from the PI fed mice contained

three times more IL-10 and twice as much IL-4 compared with MLC supernatants of placebo fed animals.

Table 2.

5 Amounts* of IL-2, IL-4 and IL-10 secreted by allo-stimulated splenocytes obtained from PI or placebo fed mice.

| 10 | Days of MLC | PI | | | Placebo | | |
|----|----------------|-------|-------|-------|---------|-------|-------|
| | | IL-2 | IL-10 | IL-4 | IL-2 | IL-10 | IL-4 |
| | | ng/ml | pg/ml | ng/ml | pg/ml | ng/ml | pg/ml |
| | 3 | 13.5 | 2.6 | 191 | 6.2 | 1.3 | 26 |
| | 4 | 0.9 | 2.9 | 54 | 0.7 | 1.0 | 27 |

15 *Amounts of cytokine per ml culture supernatant produced by MLC responder cells from a pool of five spleens, numbers represent the means of two replicate cytokine measurements.

20 **Example 4**

Study object

An extract of Parthenium integrifolium according to the
25 invention was prepared as follows:

1000 g dried root of Parthenium integrifolium was extracted with 10 000 ml of boiling 90 % ethanol for 4 hours. Thereafter the extract was filtered and evaporated
30 to dryness under vacuum. Thus 216 g of an amber-coloured crystalline extract was obtained. Tablets containing 50 mg of the extract were prepared.

Study summary***Background***

5 The object of the study was to evaluate the prophylactic effect of the extract of Parthenium integrifolium on migraine headache in an open clinical trial.

Methods

10 16 migraine sufferers with a history of at least four incidences of migraine headache a month during the last six months were included in the study.

15 The study schedule consisted of four periods of four weeks. The first period served as a baseline, where no treatment was employed. In the second period a daily dosage of 4 tablets was employed. In the third period a daily dosage of 2 tablets was employed. In the fourth pe-
20 riod a daily dosage of 4 tablets was employed. During the four periods all incidences of migraine headache were re-
corded.

Statistics

25 Wilcoxon rank sum test for paired differences was used for comparing the incidence of migraine headache in each of the three treatment periods with the incidence in the baseline period.

30

Findings

35 The mean incidence of migraine headache was 5,75 in period 1 (baseline). The mean incidence of migraine headache was 30% lower in period 2, 43% lower in period 3 and 57% lower in period 4 as compared to baseline. Period 4

was significantly different from baseline ($p<0.05$; Wilcoxon).

Interpretation

5

In this study the tested extract of *Parthenium integrifolium* was concluded to be a powerful remedy in the prophylaxis of migraine headache.

PATENT CLAIMS

1. A pharmaceutical composition containing *Parthenium integrifolium* or parts thereof or an extract or component thereof and a pharmaceutically acceptable carrier.

2. A pharmaceutical composition according to claim 1, which further comprises one or more other active ingredients.

10

3. A pharmaceutical composition according to claim 2, which further comprises γ -linolenic acid or eicosapentaenoic acid.

15

4. A pharmaceutical composition according to claim 2, which further comprises *Zingiber officinale* or parts thereof or an extract or component thereof.

20

5. The use of *Parthenium integrifolium* or parts thereof or an extract or component thereof for preparing a medicine for the enhancement of the TH2 pathway of the immune system.

25

6. The use of *Parthenium integrifolium* or parts thereof or an extract or component thereof for preparing a medicine for the enhancement of the levels of interleukin-4 and interleukin-10.

30

7. The use according to claim 6 for preparing a medicine for the selective suppression of cyclooxygenase-2 (COX-2).

8. The use according to any one of claims 5, 6 and 7 for preparing a medicine for the alleviation of pain.

9. The use according to any one of claims 5, 6 or 7 for preparing a medicine for the treatment or prevention of migraine or headache.

5 10. The use according to any one of claims 5, 6 and 7 for preparing a medicine for the treatment or prevention of inflammatory or autoimmune disorders.

10 11. A method for the alleviation of pain in an individual, characterised by administering Parthenium integrifolium or parts thereof or an extract or component thereof or a pharmaceutical composition according to any one of claims 1-4 to said individual.

15 12. A method for the treatment or prevention of an inflammatory or autoimmune disorder in an individual, characterised by administering Parthenium integrifolium or parts thereof or an extract or component thereof or a pharmaceutical composition according to any one of claims 1-4 to said individual.

20 13. A method for the treatment or prevention of migraine or headache in an individual, characterised by administering Parthenium integrifolium or parts thereof or an extract or component thereof or a pharmaceutical composition according to any one of claims 1-4 to said individual.

25 14. A method of preparing an extract of Parthenium integrifolium, which comprises extracting said plant or parts thereof, preferably the root, with an extraction agent comprising an organic solvent or a mixture thereof with water and subsequently, if necessary, removing the extraction agent to obtain an extract suitable for utilisation.

15. A method according to claim 14, wherein said solvent is a water miscible organic solvent selected from the group consisting of acetone, methyl ethyl ketone, ethyl acetate and lower alkanols having 1 to 4 carbon atoms.

5

16. A method according to claim 14 or 15, wherein the extract is further subjected to liquid-liquid extraction with a water immiscible organic solvent for the removal or concentration of certain constituents.

10

17. An extract prepared according to the method of any one of claims 14-16.

INTERNATIONAL SEARCH REPORT

| |
|-------------------------------|
| International application No. |
| PCT/DK 97/00457 |

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 35/78

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

NAPRALERT, WPI, CAPLUS, EMBASE, MEDLINE, BIOSIS, IFIPAT

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| X | DE 3638715 A1 (LOMAPHARM RUDOLF LOHMANN GMBH KG), 26 May 1988 (26.05.88) -- | 1-7,10,14-17 |
| X | US 4758433 A (EDWARD S. JOHNSON ET AL), 19 July 1988 (19.07.88) -- | 1-4,8-10, 14-17 |
| A | Drug Topics, November 1995, Edward M. Croom, Jr. et al, "Botanicals in the pharmacy: New life for old remedies", page84, see page 89 -- ----- | 1-10 |

 Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

9 January 1998

Date of mailing of the international search report

21.01.1998

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86Authorized officer

Carolina Gómez Lagerlöf
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

DK 97/00457

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 11-13
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

02/12/97

| | |
|-------------------------------|--|
| International application No. | |
| PCT/DK 97/00457 | |

| Patent document cited in search report | | Publication date | Patent family member(s) | | Publication date |
|--|---|------------------|-------------------------|-------------|------------------|
| DE 3638715 A1 | | 26/05/88 | NONE | | |
| US 4758433 | A | 19/07/88 | AR | 230008 A | 29/02/84 |
| | | | AU | 564371 B | 13/08/87 |
| | | | AU | 1464683 A | 24/11/83 |
| | | | CA | 1270843 A | 26/06/90 |
| | | | DK | 219083 A | 20/11/83 |
| | | | EP | 0098041 A,B | 11/01/84 |
| | | | SE | 0098041 T3 | |
| | | | GB | 2124486 A,B | 22/02/84 |
| | | | JP | 1705680 C | 27/10/92 |
| | | | JP | 3040012 B | 17/06/91 |
| | | | JP | 59001425 A | 06/01/84 |